Education and Training
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: inotuzumab ozogamicin
- drug: FLAG (fludarabine, cytarabine and G-CSF)
- drug: HIDAC (high dose cytarabine)
- drug: cytarabine and mitoxantrone
Eligibility
Inclusion Criteria:
- CD22 expression
- Adequate liver and renal functions
Exclusion Criteria:
- Isolated extramedullary disease
- Active Central Nervous System [CNS] disease
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting